Biocon Biologics

Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company and India's first publicly listed biotech enterprise.

An independent entity, with its own dedicated management, Biocon Biologics consolidates the development, manufacturing and commercialization operations of Biocon’s biosimilars business.

Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting-edge class of therapies to patients globally. It is the only fully integrated pure play biosimilars organization in the world. The company aspires to transform patient lives through innovative and inclusive healthcare solutions. It has one of the largest global biosimilars portfolios, spanning recombinant human Insulin (rh-Insulin), insulin analogs, monoclonal antibodies and other recombinant proteins for diabetes, cancer, autoimmune conditions and other life-threatening diseases. The company has multiple commercial-scale manufacturing platforms with capacities to support a global play.

The Company has over the years benefited the lives of millions of patients and built credibility globally as a strong biosimilars player. Its scientific know-how, technological expertise and global scale manufacturing capabilities have positioned it ahead of the curve in the realm of biosimilars. Today, it has a large portfolio of biosimilars under global clinical development with three of these commercialized in at least one of the developed markets of EU, U.S. and Japan.

OUR EXPERTISE

Our Science

In pursuit of our objective of enhancing global healthcare through innovative and affordable biopharmaceuticals, Biocon’s Research and Development (R&D) function has built world-class competence and capability on the back of robust infrastructure and a talent pool that has extensive global product development experience.

R&D's core strategy is based on integrated discovery, stage gated approach to development, core disease area expertise (autoimmune and inflammation, oncology and diabetes), and a first-rate scientific advisory board.

Global Scale Manufacturing

We have globally compliant manufacturing facilities across diverse technology platforms spanning insulin analogs, monoclonal antibodies and other recombinant proteins. We have built one of India's largest bio-manufacturing facilities for insulins, monoclonal antibodies and devices. Our insulin manufacturing and R&D facility in Malaysia is the largest integrated insulins facility in Asia. We continue to expand our infrastructure in a capital efficient, modular way.

Highest Standards of Quality & Compliance

Biocon Biologics' state-of-the-art manufacturing facilities are qualified by various regulatory agencies from developed and emerging markets. With an unwavering commitment to quality assurance and stringent quality controls, the Company is on a mission to go beyond compliance and achieve global standards of excellence.

Biosimilars Frontrunner

As a frontrunner in biosimilars, Biocon Biologics is addressing the needs of patients for affordable biologics across many developed and emerging markets through its recombinant human Insulin, Insulin Glargine, biosimilar Trastuzumab and other biopharmaceuticals.

Wide Global Footprint

The Company is serving patients in U.S., EU, Japan, Latin America, Africa, Middle East and Turkey and the Asia-Pacific regions through its wide biosimilar portfolio and has gained a broad experience in managing the risks entailed in taking advanced therapies from 'bench to bedside' even in the most stringently regulated markets.

OUR PRODUCT PIPELINE

Currently, Biocon Biologics has a 200,000 sq. ft state of the art Research & Development Centre at Biocon Park, Bengaluru, India. The Company has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own.

THERAPY FOCUS: Diabetes, Oncology, Immunology, Dermatology, Ophthalmology, Neurology, Rheumatology and Inflammatory Diseases.

Patient Centricity

We are working to create a patient ecosystem that offers unique patient experience. We are aiming to offer innovative healthcare solutions.

• Serving patient needs with high quality affordable biosimilars
• 2+ billion doses cumulatively of biosimilar insulins provided to patients globally
• 5 biosimilars commercialized so far: Trastuzumab, Pegfilgrastim, Bevacizumab, rh-Insulin, Insulin Glargine
• ~2 million* patients served globally through our biosimilars in FY19
• Aiming to impact ~2.6 million* patient lives worldwide in FY20
• Aspire to touch 5 Million patient lives by FY22
• *Number of lives is calculated based on volume supplied